{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ01286",
      "entity_text" : "FIXa-AT",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "TissueType" : [ "tissuelist:TS-0079" ],
      "Species" : [ "taxonomy:9606" ]
    }
  },
  "verbose_text" : "No difference was found in FIXa-AT levels (94.0 +/- 27.1 vs. 94.5 +/- 34.0; p = 0.93), FXa-AT levels (282.0 +/- 57.4 vs. 296.4 +/- 54.6; p = 0.14), and TAT levels (4.0 [IQR : 3.1-5.0] vs. 3.8 [IQR : 3.0-4.9]; p = 0.71) between the vorapaxar-group and placebo-group (XREF_FIG).",
  "reading_complete" : "2020-08-03T12:40:21Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T12:39:34Z",
  "trigger" : "levels",
  "evidence" : [ "FIXa-AT levels" ],
  "pmc_id" : "6697509",
  "score" : 0
}